NEW YORK, June 18, 2024 /PRNewswire/ -- The global endocrinology drugs market  size is estimated to grow by USD 36.83 mn from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of over 7.45%  during the forecast period.  Increase in incidence of endocrine disorders is driving market growth, with a trend towards association between obesity and endocrine disorders. However, patent expiry of major endocrinology drugs  poses a challenge. Key market players include Abbott Laboratories, Acerus Pharmaceuticals Corp., Ascendis Pharma AS, Bayer AG, Beta Cell NV, Biocon Ltd., Eli Lilly and Co., Endo International Plc, F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Hanmi Pharm Co. Ltd., Ipsen Pharma, Merck and Co. Inc., Novartis AG, Novo Nordisk AS, Oramed Pharmaceuticals Inc., Pfizer Inc., Sanofi SA, Takeda Pharmaceutical Co. Ltd., and VeroScience LLC.

Get a detailed analysis on regions, market segments, customer landscape, and companies - Click for the snapshot of this report

Key Market Trends Fueling Growth

The obesity epidemic is linked to a rise in endocrine disorders, including diabetes, hypothyroidism, and PCOS. These conditions can cause or result from obesity. Endocrine disorders related to obesity can often be managed through weight loss. Obesity, type-2 diabetes mellitus, and thyroid diseases are common co-occurring conditions. Hypothyroidism is the most frequent causative factor, leading to reduced metabolic efficiency, increased water retention, and decreased lipolysis. Sedentary lifestyles, smoking, and dietary changes contribute to both obesity and endocrine disorders. This association drives the growth of the global endocrinology drugs market. 

The endocrinology drugs market is experiencing significant growth due to the increasing prevalence of endocrine disorders such as diabetes, hypothyroidism, and hyperthyroidism. The market is driven by the development of new treatments and therapies, including synthetic hormones and insulin derivatives. Hormone replacement therapies are also gaining popularity for the treatment of menopausal symptoms. Additionally, the use of biologics and peptide-based drugs is on the rise, as they offer more targeted and effective treatments. The market is competitive, with major players investing in research and development to bring innovative products to market. The use of technology, such as telemedicine and digital health solutions, is also transforming the way endocrinology drugs are delivered and administered. Overall, the endocrinology drugs market is expected to continue growing in the coming years. 

Research report provides comprehensive data on impact of trend. For more details- Download a Sample Report

Market Challenges

• Endocrinology drugs, such as PREMPRO and PREMPHASE, have been available since the late 1990s. However, patent expiry for many of these medications, including Lantus and Humalog, has led to the entry of generic alternatives and decreased market share for branded drugs. Manufacturers employ strategies like clustered patents and patent litigations to delay generic entry. Post-patent expiry, biosimilars have improved treatment affordability and accessibility for endocrine disorders, but face payer resistance. Notable drugs with upcoming patent expiry include BYETTA, Victoza, APIDRA, and JANUVIA.
• The Endocrinology Drugs Market faces several challenges in the reproduction and discovery of new treatments. These include the complexity of endocrine systems and disorders, the need for personalized medicine, and the high cost of research and development. Additionally, regulatory requirements and ethical considerations add to the challenges. For instance, the discovery of new hormones and their receptors is a complex process. Furthermore, personalized medicine requires a deep understanding of individual patient needs, which can be challenging to achieve. Lastly, the high cost of research and development, coupled with regulatory hurdles, can make bringing new endocrinology drugs to market a lengthy and expensive process.

For more insights on driver and challenges - Download a Sample Report

Segment Overview 

This endocrinology drugs market report extensively covers market segmentation by

1. Therapy Area
   • 1.1 Diabetes drugs
   • 1.2 hGH
   • 1.3 Thyroid hormone disorders
   • 1.4 Others
2. Distribution Channel
   • 2.1 Hospital pharmacies
   • 2.2 Retail pharmacies
   • 2.3 Online pharmacies
3. Geography 
   • 3.1 North America
   • 3.2 Europe
   • 3.3 Asia
   • 3.4 Rest of World (ROW)

1.1 Diabetes drugs-  The Endocrinology Drugs Market is experiencing steady growth due to the increasing prevalence of diabetes and other endocrine disorders. Key players in this market include Sanofi, Novo Nordisk, and Eli Lilly. They offer treatments for diabetes, thyroid disorders, and growth hormone deficiencies. Market expansion is driven by rising demand for effective and affordable medicines. Collaborations and acquisitions are common strategies to enhance product portfolios and gain a competitive edge.

For more information on market segmentation with geographical analysis including forecast (2024-2028) and historic data (2018 - 2022)  - Download a Sample Report

Research Analysis

The Endocrinology Drugs Market encompasses a range of pharmaceutical products designed to treat disorders of the endocrine system. These disorders can include hormonal imbalances resulting from conditions affecting the pancreas, thyroid, parathyroid, adrenals, testes, ovaries, pituitary, and hypothalamus. The market includes drugs that target amines, steroids, peptides, and proteins, playing crucial roles in metabolism, reproduction, and the regulation of various bodily functions. Endocrinologists frequently prescribe medications such as Levothyroxine Sodium Injection for thyroid disorders, Teneligliptin, Pioglitazone, and Metformin for managing Type 2 diabetes. Unhealthy lifestyle characteristics, including work stress and weight gain, can contribute to hormonal imbalances and the need for these medications. Cholesterol levels can also be affected by endocrine disorders, making the development of effective treatments a priority in this market.

Market Research Overview

The Endocrinology Drugs Market encompasses a variety of treatments for disorders related to the endocrine system. These conditions include diabetes, thyroid disorders, pituitary disorders, and hormonal imbalances. The market is driven by the rising prevalence of endocrine disorders and the increasing demand for effective and safe treatments. The market is segmented based on drug classes, such as insulins, oral antidiabetics, thyroid hormones, and growth hormones. The market is also influenced by factors like regulatory policies, technological advancements, and pricing trends. The use of advanced technologies like biosimilars and generic drugs is expected to increase competition in the market. The market is projected to grow significantly in the forecast period due to the increasing burden of endocrine disorders and the development of new and innovative treatments.

Table of Contents:

1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation

• Therapy Area
• • Diabetes Drugs
  • HGH
  • Thyroid Hormone Disorders
  • Others
• Distribution Channel
• • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Geography
• • North America
  • Europe
  • Asia
  • Rest Of World (ROW)

7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

View original content to download multimedia:https://www.prnewswire.com/news-releases/endocrinology-drugs-market-size-is-set-to-grow-by-usd-36-83-billion-from-2024-2028--increase-in-incidence-of-endocrine-disorders-to-boost-the-market-growth-technavio-302174097.html

SOURCE Technavio